These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32615260)

  • 21. Lipid Nanoemulsions of Rebamipide: Formulation, Characterization, and In Vivo Evaluation of Pharmacokinetic and Pharmacodynamic Effects.
    Narala A; Guda S; Veerabrahma K
    AAPS PharmSciTech; 2019 Jan; 20(1):26. PubMed ID: 30604333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
    Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
    Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
    Lennernäs H
    Curr Drug Metab; 2007 Oct; 8(7):645-57. PubMed ID: 17979653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A modified physiological BCS for prediction of intestinal absorption in drug discovery.
    Zaki NM; Artursson P; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
    Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
    Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa.
    Ishihara K; Komuro Y; Nishiyama N; Yamasaki K; Hotta K
    Arzneimittelforschung; 1992 Dec; 42(12):1462-6. PubMed ID: 1337697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
    Masaoka Y; Tanaka Y; Kataoka M; Sakuma S; Yamashita S
    Eur J Pharm Sci; 2006 Nov; 29(3-4):240-50. PubMed ID: 16876987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids.
    Miyake M; Minami T; Hirota M; Toguchi H; Odomi M; Ogawara K; Higaki K; Kimura T
    J Control Release; 2006 Mar; 111(1-2):27-34. PubMed ID: 16410031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rebamipide nanocrystal with improved physicomechanical properties and its assessment through bio-mimicking 3D intestinal permeability model.
    Samim Sardar M; Kashinath KP; Kumari M; Sah SK; Alam K; Gupta U; Ravichandiran V; Roy S; Kaity S
    Nanoscale; 2024 Oct; 16(42):19786-19805. PubMed ID: 39370903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral absorption of anti-aids nucleoside analogues: 3. Regional absorption and in vivo permeability of 2',3'-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model.
    Sinko PJ; Sutyak JP; Leesman GD; Hu P; Makhey VD; Yu H; Smith CL
    Biopharm Drug Dispos; 1997 Nov; 18(8):697-710. PubMed ID: 9373726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of rebamipide-loaded spray-dried microsphere using distilled water and meglumine: physicochemical characterization and pharmacokinetics in rats.
    Ko DW; Cho JH; Choi HG
    Pharm Dev Technol; 2021 Jul; 26(6):701-708. PubMed ID: 33938359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.
    Lennernäs H
    Mol Pharm; 2014 Jan; 11(1):12-23. PubMed ID: 24206063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion.
    Lozoya-Agullo I; Zur M; Beig A; Fine N; Cohen Y; González-Álvarez M; Merino-Sanjuán M; González-Álvarez I; Bermejo M; Dahan A
    Int J Pharm; 2016 Dec; 515(1-2):201-208. PubMed ID: 27667756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells.
    Miyake M; Nakai D
    Xenobiotica; 2017 Sep; 47(9):821-824. PubMed ID: 27557477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biopharmaceutics classification and intestinal absorption study of apigenin.
    Zhang J; Liu D; Huang Y; Gao Y; Qian S
    Int J Pharm; 2012 Oct; 436(1-2):311-7. PubMed ID: 22796171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.
    Cao X; Gibbs ST; Fang L; Miller HA; Landowski CP; Shin HC; Lennernas H; Zhong Y; Amidon GL; Yu LX; Sun D
    Pharm Res; 2006 Aug; 23(8):1675-86. PubMed ID: 16841194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts.
    Macheras P; Chryssafidis P
    Pharm Res; 2020 Sep; 37(10):187. PubMed ID: 32888087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.